Mr. Baron brings to Janus an extensive experience in the pharmaceutical industry as a Partner at Extera Partners; SVP of Corporate Development at BioAssets; a member of the M&A Team at Millennium Pharmaceuticals; and Consultant for Booz Allen.
Dr. Lipford has over 25 years of research experience in field of immunology at Selecta, Pfizer, Coley Pharmaceuticals, and TUM, 15 of which have been in the area of Toll-Like Receptors (TLRs). He is an author on over 100 publications and named as an inventor on over 30 primary patents.
Dr. Jonathan Reis, an experienced life science entrepreneur with over 25 years of executive management. Jonathan’s expertise covers a variety of industry segments including cardiology, autoimmune, gastroenterology, general surgery, orthopedics, wound care, patient monitoring, primary care, and IV diagnostics. Prior to Extera, Jonathan founded several medical device start-up companies and was involved in venture capital investment activities. He earned his MD from the Technion Institute of Technology and his MBA from the Harvard Business School. He is currently a security industry professional and a Registered Representative with FINRA.
Mrs. de los Reyes is currently the VP of Strategic Planning and Business Development for Alopexx. She has over twenty two years of pharmaceutical experience and advises life science companies on partnering strategy, search for potential partners, coordination of technical evaluation and due diligence, deal structure and transaction negotiation. Prior to her role with Alopexx, she was Executive Director of Licensing & Development at Pfizer, where she spent twelve years in their licensing group with a focus on in-licensing in several therapeutic areas including neuroscience, infectious diseases, immunology, dermatology, and ophthalmology.